90 participants
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-22
- Start Date:
- 2025-07-09
- Completion:
- 2028-01-31
Conditions
- Refractory Rheumatoid Arthritis (RA)
- Idiopathic Inflammatory Myopathies (IIMs)
- Systemic Sclerosis (SSc)
- Rheumatoid Arthritis (RA
- IIM
- Myositis
- Scleroderma
- Sjogren Syndrome
- Sjogrens Disease
Interventions
- DRUG
No Results Yet